THE ROLE OF PURIFIED CD8+ T CELLS IN GRAFT-VERSUS-LEUKEMIA ACTIVITY AND ENGRAFTMENT AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION

1995 ◽  
Vol 60 (4) ◽  
pp. 355-361 ◽  
Author(s):  
V. PALATHUMPAT ◽  
S. DEJBAKHSH-JONES ◽  
S. STROBER
Blood ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 1522-1529 ◽  
Author(s):  
Kai Sun ◽  
Minghui Li ◽  
Thomas J. Sayers ◽  
Lisbeth A. Welniak ◽  
William J. Murphy

Abstract Dissociating graft-versus-tumor (GVT) effect from acute graft-versus-host disease (GVHD) still remains a great challenge in allogeneic bone marrow transplantation (allo-BMT). Bortezomib, a proteasome inhibitor, has shown impressive efficacy as a single agent in patients with hematologic malignancies but can result in toxicity when administered late after allogeneic transplantation in murine models of GVHD. In the current study, the effects of T-cell subsets and their associated cytokines on the efficacy of bortezomib in murine allogeneic BMT were investigated. Increased levels of serum tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ) were observed after allo-BMT and continuous bortezomib administration. Bortezomib-induced GVHD-dependent mortality was preventable by depletion of CD4+ but not CD8+ T cells from the donor graft. The improved survival correlated with markedly reduced serum TNFα but not IFNγ levels. Transfer of Tnf−/− T cells also protected recipients from bortezomib-induced GVHD-dependent toxicity. Importantly, prolonged administration of bortezomib after transplantation of purified CD8+ T cells resulted in enhanced GVT response, which was dependent on donor CD8+ T cell–derived IFNγ. These results indicate that decreased toxicity and increased efficacy of bortezomib in murine allo-BMT can be achieved by removal of CD4+ T cells from the graft or by inhibiting TNFα.


2008 ◽  
Vol 59 (6) ◽  
pp. 635-636
Author(s):  
T. M. Kollgaard ◽  
S. Reker ◽  
S. L. Petersen ◽  
T. N. Masmas ◽  
L. L. Vindelov ◽  
...  

Blood ◽  
2018 ◽  
Vol 132 (22) ◽  
pp. 2351-2361 ◽  
Author(s):  
Lauren P. McLaughlin ◽  
Rayne Rouce ◽  
Stephen Gottschalk ◽  
Vicky Torrano ◽  
George Carrum ◽  
...  

Abstract There is a Blood Commentary on this article in this issue.


Blood ◽  
1997 ◽  
Vol 90 (2) ◽  
pp. 873-885 ◽  
Author(s):  
Margot Zöller ◽  
Annette Schmidt ◽  
Angela Denzel ◽  
Jürgen Moll

Abstract Constitutive expression of a rat CD44 variant isoform, rCD44v4-v7, on murine T cells accelerates immune responsiveness. Because prolonged immunodeficiency can be a major drawback in allogeneic bone marrow transplantation, we considered it of special interest to see whether repopulation of lethally irradiated syngeneic and allogeneic mice may be influenced by constitutive expression of the rCD44v4-v7 transgene. When lethally irradiated syngeneic and allogeneic mice were reconstituted with bone marrow cells (BMC) from rCD44v4-v7 transgenic (TG) or nontransgenic (NTG) mice, the former had a clear repopulation advantage: thymocytes expanded earlier after reconstitution and, as a consequence, higher numbers of lymphocytes were recovered from spleen and lymph nodes. Lymphocytes also displayed functional activity in advance to those from mice reconstituted with BMC from NTG mice. Most importantly, after the transfer of BMC from TG mice into an allogeneic host, the frequency of host-reactive T cells decreased rapidly. Apparently, this was due to accelerated induction of tolerance. Because these effects were counterregulated by an rCD44v6-specific antibody, it is likely that they could be attributed to the rCD44v4-v7 TG product. Thus, expression of a CD44 variant isoform at high levels facilitated reconstitution with allogeneic BMC by accelerated establishment of tolerance and the regaining of immunocompetence.


Sign in / Sign up

Export Citation Format

Share Document